This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • External Eye Disease  • Dermatology  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Joshua C. Priluck, MD; Selena Fu, MD

Arch Ophthalmol. 2010;128(6):792-793.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Bimatoprost solution, 0.3% (Latisse; Allergan Inc, Irvine, California), is a synthetic prostaglandin analogue indicated for the treatment of hypotrichosis and dispensed separately to lower intraocular pressure (Lumigan, 0.3%; Allergan Inc). For the treatment of hypotrichosis, Latisse is used as a single drop on a sterile applicator and applied to the patient's upper eyelid skin at the eyelash margin daily at night.

The prescribing information for Latisse¹ includes warnings related to skin changes such as possible lid pigmentation of the periorbital tissue and hair growth outside the treatment area. The most common adverse events caused by Latisse use are described as eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These common adverse events have been described in less than 4% of patients.

We describe 4 cases of Latisse-induced hyperpigmentation of the eyelid skin using the eyelid . . . [Full Text of this Article]

Report of Cases

Case 1

Case 2

Case 3

Case 4

Comments

AUTHOR INFORMATION
Author Affiliations: Summa Health Systems (Drs Priluck and Fu), and Akron Children's Hospital (Dr Fu), Akron, Ohio.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter     What's this?